No Data
bluebird bio (NASDAQ:BLUE) Trading Up 12.6%
bluebird bio, Inc. (NASDAQ:BLUE – Get Rating)'s share price was up 12.6% during mid-day trading on Thursday . The company traded as high as $6.76 and last traded at $6.68. Approximately 174,236 share
Head-To-Head Survey: bluebird bio (NASDAQ:BLUE) and Vaxart (NASDAQ:VXRT)
bluebird bio (NASDAQ:BLUE – Get Rating) and Vaxart (NASDAQ:VXRT – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the
BLUE, INVZ and AQST are among pre market gainers
Euro Tech Holdings Company (CLWT) +39%. SilverSun Technologies (SSNT) +28%. Aethlon Medical (AEMD) +19%CEO Chuck Fisher on Q1 2023 Results - Earnings Call Transcript. The Trade Desk (TTD) +16% Inc. 2
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ:AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.BBQ Holdings, Inc. (NASDAQ
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US
Barclays says that CRISPR Therapeutics AG's (NASDAQ: CRSP) Q2 FY22 earnings release was largely incremental, highlighting the progress of multiple clinical programs, including the goal of on-track reg
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
Gainers Verona Pharma plc (NASDAQ:VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD
Why Is BIMI International Medical Higher By Around 70%: Here Are 38 Stocks Moving Premarket
Gainers BIMI International Medical Inc. (NASDAQ:BIMI) shares rose 69.6% to $1.04 in pre-market trading after Fnu Oudom reported a stake of 44% in the company in 13D.Ontrak, Inc. (NASDAQ:OTRK) shares r
Andrew Obenshain Sells 21,805 Shares of bluebird bio, Inc. (NASDAQ:BLUE) Stock
bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) CEO Andrew Obenshain sold 21,805 shares of the company's stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $4.
bluebird bio, Inc. (NASDAQ:BLUE) CEO Andrew Obenshain Sells 21,805 Shares
bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) CEO Andrew Obenshain sold 21,805 shares of the business's stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of
Barclays Lifts bluebird bio to Equalweight From Underweight, Price Target to $5 From $3
04:45 AM EDT, 08/08/2022 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Loading...